{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T16:12:55Z","timestamp":1778343175257,"version":"3.51.4"},"reference-count":39,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/ol.2016.5058","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T08:26:03Z","timestamp":1472459163000},"page":"3101-3114","source":"Crossref","is-referenced-by-count":16,"title":["Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125"],"prefix":"10.3892","volume":"12","author":[{"given":"Anita","family":"Chudecka-G\u0142az","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Cymbaluk-P\u0142oska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Luterek-Puszy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Menkiszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"key20180108110931_b1-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"key20180108110931_b2-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999\u20132007 by country and age: Results of EUROCARE-5-a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20180108110931_b3-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.10.023","article-title":"Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival","volume":"136","author":"Cliby","year":"2015","journal-title":"Gynecol Oncol"},{"key":"key20180108110931_b4-ol-0-0-5058","first-page":"408","article-title":"Comparison of different ovarian cancer detection algorithms","volume":"32","author":"Macucs","year":"2011","journal-title":"Eur J Gynecol Oncol"},{"key":"key20180108110931_b5-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.1999.tb08318.x","article-title":"Comparison of two malignancy risk indices based on serum Ca125, ultrasound score and menopausal status in the diagnosis of ovarian masses","volume":"106","author":"Morgante","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"key20180108110931_b6-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00006250-199903000-00028","article-title":"The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals","volume":"93","author":"Tinglustad","year":"1999","journal-title":"Obstet Gynecol"},{"key":"key20180108110931_b7-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/1055-9965.EPI-10-0580","article-title":"The road from discovery to clinical diagnostics: Lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers","volume":"19","author":"Zhang","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180108110931_b8-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/AOG.0b013e31821b1d80","article-title":"Performance of the American collage of obstetricians and gynecologists' ovarian tumor referral guidelines with multivariate index assay","volume":"117","author":"Miller","year":"2011","journal-title":"Obstet Gynecol"},{"key":"key20180108110931_b9-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet Gynecol"},{"key":"key20180108110931_b10-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2013.01.018","article-title":"A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with adnexal mass","volume":"129","author":"Kaijser","year":"2013","journal-title":"Gynecol Oncol"},{"key":"key20180108110931_b11-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"key20180108110931_b12-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"key20180108110931_b13-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","article-title":"Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management","volume":"20","author":"Bandiera","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180108110931_b14-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0b013e318234f852","article-title":"The utility of human epididymal protein 4, cancer antigen 125, and risk form malignancy algorithm in ovarian cancer and endometriosis","volume":"22","author":"Kadija","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"key20180108110931_b15-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1007\/s13277-014-1811-6","article-title":"Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: A meta analysis","volume":"35","author":"Wang","year":"2014","journal-title":"Tumor Biol"},{"key":"key20180108110931_b16-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/uog.12551","article-title":"Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?","volume":"43","author":"Kaijser","year":"2014","journal-title":"Ultrasound Obstet Gynecol"},{"key":"key20180108110931_b17-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13277-012-0440-1","article-title":"An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: Use in differentiation of ovarian cancers and benign lesions","volume":"33","author":"Macus","year":"2012","journal-title":"Tumor Biol"},{"key":"key20180108110931_b18-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs. the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"key20180108110931_b19-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecological disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"key20180108110931_b20-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00404-013-2722-2","article-title":"Evaluation of HE4 as an extra biomarker to CA125 to improve detection of ovarian carcinoma: Is it time for step forward?","volume":"288","author":"Azzam","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"key20180108110931_b21-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","article-title":"Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases","volume":"44","author":"Park","year":"2011","journal-title":"Clin Biochem"},{"key":"key20180108110931_b22-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: A systematic review and meta-analysis","volume":"167","author":"Lin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20180108110931_b23-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: A systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"key20180108110931_b24-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"437","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"key20180108110931_b25-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: A prospective case control study in Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key20180108110931_b26-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1007\/s13277-014-1945-6","article-title":"HE4, CA125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer","volume":"35","author":"Ortiz-Mu\u00f1oz","year":"2014","journal-title":"Tumor Biol"},{"key":"key20180108110931_b27-ol-0-0-5058","first-page":"2081","article-title":"The diagnostic accuracy of two human epididymis protein 4 (HE4) testing system in combination with CA125 in the differential diagnosis of ovarian masses","volume":"49","author":"Lenhardt","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key20180108110931_b28-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1757-2215-5-20","article-title":"High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer","volume":"5","author":"Kalapotharakos","year":"2012","journal-title":"J Ovarian Res"},{"key":"key20180108110931_b29-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggieri","year":"2011","journal-title":"Clin Chim Acta"},{"key":"key20180108110931_b30-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.clinbiochem.2013.08.019","article-title":"The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay","volume":"46","author":"Yang","year":"2013","journal-title":"Clin Biochem"},{"key":"key20180108110931_b31-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: Is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"key20180108110931_b32-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2011.12.003","article-title":"Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses","volume":"48","author":"Van Gorp","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180108110931_b33-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"193","DOI":"10.17772\/gp\/2062","article-title":"Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses","volume":"86","author":"Janas","year":"2015","journal-title":"Ginekol Pol"},{"key":"key20180108110931_b34-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"HE4 a novel tumor marker for ovarian cancer: Comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumor Biol"},{"key":"key20180108110931_b35-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3802\/jgo.2011.22.4.244","article-title":"Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass","volume":"22","author":"Partheen","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"key20180108110931_b36-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"803598","DOI":"10.1155\/2014\/803598","article-title":"Borderline ovarian tumors and diagnostic dilemma of intraoperative diagnosis: Could preoperative He4 assay and ROMA score assessment increase the frozen section accuracy? A multicentre case-control study","volume":"2014","author":"Gizzo","year":"2014","journal-title":"Biomed Res Int"},{"key":"key20180108110931_b37-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","article-title":"Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up","volume":"90","author":"Olivier","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180108110931_b38-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/ejhg.2009.60","article-title":"Risk-reducucing surgery for ovarian cancer: Outcomes in 300 surgeries suggest a low peritoneal primary risk","volume":"17","author":"Evans","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"key20180108110931_b39-ol-0-0-5058","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/01.pas.0000202161.80739.ac","article-title":"Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutations carriers, with emphasis on fallopian tube lesions: Report of 6 cases and review of the literature","volume":"30","author":"Carcangiu","year":"2006","journal-title":"Am J Surg Pathol"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.5058\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T14:56:25Z","timestamp":1515423385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.5058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,8,29]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/ol.2016.5058"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.5058","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,29]]}}}